COVID-19 Immunity Testing
Measuring SARS-CoV-2 T cell and antibody responses to address the COVID-19 pandemic.
T Cell Testing Service
ImmunoServ offers a truly scalable T cell and antibody testing service for measuring COVID-19 immunity in large cohorts and population studies.
Our scientists are experts in the T cell immunology field, with a combined 95 publications measuring T cell responses to viruses, bacteria and cancer.
Drawing on our expertise in measuring adaptive immune responses to viruses, ImmunoServ has created the COVID-19 Immuno-T™ test, a simple high-throughput whole blood-based assay demonstrating 96.0% sensitivity for determining prior COVID-19 infection or vaccination status.2
We provide an end-to-end service including blood sample collection, UN3373 compliant logistics, full analysis, and data interpretation.
The COVID-19 Immuno-T™ Test
The COVID-19 Immuno-T™ test is an easily adaptable assay capable of measuring both antibody and T cell responses to SARS-CoV-2 wild-type, delta or omicron variants. It can also differentiate between prior infection and vaccine-induced immune responses.
The test has been used in multiple research studies to measure SARS-CoV-2-specific T cell and antibody responses in healthy donors2, cancer patients2, people with multiple sclerosis3 and other immune compromised patients4.
The test has shown that the magnitude of venous or capillary blood-derived SARS-CoV-2-specific T cell response is an important correlate of protection, accurately determining COVID-19 immunity1.
Throughout 2021, ImmunoServ has been involved on the COVID IMMUNE study, funded by the UK government. This joint project run by Cardiff University and Velindre Cancer Centre utilised the COVID-19 Immuno-T test to measure SARS-CoV-2 T cell and antibody responses induced by prior infection and/or vaccination in ~300 donors. Given the test’s high-throughput nature, our laboratory scientists easily performed the assay on over 1000 blood samples, with results reported back to each donor within 48 hours. Data is now being used to identify at-risk individuals who failed to mount sufficient immune responses to vaccination and inform their clinical care.
Our Clients
ImmunoServ's T cell and antibody testing service is supporting several public health bodies and research institutes providing significant insight into COVID-19 immunity.
If you are interested in using our COVID-19 T cell and antibody testing service, please contact us.
Now Available
At ImmunoServ we are on a mission to bring T cell testing to the masses. The World's first At-Home COVID-19 T cell test is now available to anyone in the United Kingdom.
If you would like to test your own T cell immune response to COVID-19 using the At Home Immuno-T test, please visit our Immuno-T website.
References
1. Scurr MJ et al. (2022). Magnitude of venous or capillary blood-derived SARS-CoV-2-specific T cell response determines COVID-19 immunity. Nature Communications.
2. Scurr MJ et al. (2021). Whole blood‐based measurement of SARS‐CoV‐2‐specific T cells reveals asymptomatic infection and vaccine immunogenicity in healthy subjects and patients with solid‐organ cancers. Immunology.
3. Tallantyre E, Vickaryous N, et al. (2021). COVID‐19 Vaccine Response in People with Multiple Sclerosis. Annals of Neurology.
4. Ponsford M, et al. (2021). Persistent COVID-19 Infection in Wiskott-Aldrich Syndrome Cleared Following Therapeutic Vaccination: a Case Report. Journal of Clinical Immunology.